Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisition

WuXi XDC Cayman

24/08/2026 12:34

Overview
China bioconjugate CRDMO's H1 2026 revenue grew 37% yr/yr to RMB3.7 bln
Adjusted net profit for H1 2026 rose 37.4% yr/yr, margin stable at 27.8%
Company completed BioDlink acquisition, strengthening manufacturing and expanding customer network

Outlook
Company plans to expand ADC manufacturing capacity with nearly RMB8 bln allocated through 2030
Company expects industry tailwinds to support global footprint and sustained long-term growth
Company says capacity expansion milestones are underway in China and Singapore to meet demand

Result Drivers
BIODLINK ACQUISITION - Co said BioDlink acquisition expanded manufacturing capacity and customer network
PROJECT PIPELINE EXPANSION - Co said newly signed integrated projects and increased service backlog supported revenue growth
PROPRIETARY TECHNOLOGY LICENSING - Co said licensing agreements for WuXiTecan-2TM platform contributed to results

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
 
RMB 3.7 bln
 
H1 Net Income Attributable
 
RMB 819.3 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for WuXi XDC Cayman Inc is HK$80.00, about 14.6% above its August 24 closing price of HK$69.80
The stock recently traded at 32 times the next 12-month earnings vs. a P/E of 27 three months ago

Reuters Recommended Reads
Aug 24 - China's InnoCare Pharma H1 revenue surges, partly on orelabrutinib growth
Aug 21 - China's Henlius H1 revenue jumps on drug sales, license income
Aug 24 - Sinopharm interim revenue edges down on softness in pharmaceutical distribution business

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

Press Release s3://eap-prd-eu-west-1-source-content/eap_feed_proxy/fingerpost/HKSW/2026-08-24/39162ecd-163f-441c-81a7-3c15da5a96b3.file
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)